Vaccination against COVID-19 with suspected anaphylaxis after the first dose of the vaccine Review article
Article Sidebar
Main Article Content
Abstract
With the increasing number of vaccinations against COVID-19, the rate of reported reactions with a different clinical manifestation after vaccination has increased. Although these reactions are relatively rare and not always allergic in nature, they are fearful. Particularly, patients who experienced side effects after vaccination are often not eligible for subsequent doses of the same vaccine. The diagnosis of a severe anaphylactic reaction after administration of the mRNA vaccine and/or allergy to the components of the vaccine are contraindications to vaccination with the COVID-19 mRNA vaccine.
The presented case of a patient highlights the problem of the correct qualification of the reactions that manifested during vaccination with the Comirnaty (Pfizer/BioNTech) mRNA vaccines and subsequent allergological diagnostics.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Kruszewski J, Cichocka-Jarosz E, Czarnobilska E et al. Rekomendacje Polskiego Towarzystwa Alergologicznego dotyczące kwalifikacji osób z alergią i anafilaksją do szczepienia przeciw COVID-19. Alergologia Polska – Polish Journal of Allergology 2021; 8(1): 1-8. http://doi.org/10.5114/pja.2021.104220.
3. McNeil MM, Weintraub ES, Duffy J et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin. Immunol. 2016; 137: 868-78. http://doi.org/10.1016/j.jaci.2015.07.048.
4. Centers for Disease Control and Prevention COVID-19 Response Team Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14–23, 2020. MMWR. 2021; 70: 46-51.
5. Centers for Disease Control and Prevention Newsroom. Press Briefing Transcript; January 6, 2021. Transcript: CDC Update on COVID-19. (access: 11.01.2021).
6. CDC COVID-19 Response Team. Vol. 70. 2021. Food and Drug Administration, Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020–January 10, M.M.W.R: 125-9.
7. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2020; S2213-2198(20). http://doi.org/10.1016/j.jaip.2020.09.029.31007-2.
8. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016; 46: 907-22. http://doi.org/10.1111/cea.12760.
9. Stone CA Jr, Liu Y, Relling MV et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019; 7: 1533-40.e8.
10. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis) J Allergy Clin Immunol Pract. 2021; 9: 670-5.
11. Broyles AD, Banerji A, Barmettler S et al. Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs. J Allergy Clin Immunol Pract. 2020; 8: S16-S116.
12.Dreskin SC, Halsey NA, Kelso JM. International Consensus (ICON): allergic reactions to vaccines. World Allergy Org J. 2016; 9: 32. http://doi.org/10.1186/s40413-016-0120-5.
13. Klimek L, Jutel M, Akdis CA et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – an EAACI-ARIA position paper. Allergy. 2020. http://doi.org/10.1111/all.14726.
14. Banerji A, Wickner PG, Saff R et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021; 9(4): 1423-37.